Overview

* Kura Oncology reports Q3 2025 net loss of $74.1 mln, up from $54.4 mln in 2024

* Collaboration revenue for Q3 2025 was $20.8 mln, compared to none in Q3 2024

* Company's ziftomenib program under FDA Priority Review, PDUFA date set for Nov 30, 2025

Outlook

* Kura Oncology ( KURA ) expects FDA decision on ziftomenib by November 30, 2025

* Company plans to present clinical data at ASH Annual Meeting in December 2025

* Kura expects to fund operations into 2027 with current cash and collaboration payments

Result Drivers

* MILESTONE PAYMENTS - Received two $30 mln milestone payments from Kyowa Kirin for KOMET-017 trial progress

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $20.75

Collabor mln

ation

Revenue

Q3 Net -$74.11

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Kura Oncology Inc ( KURA ) is $27.00, about 63.8% above its November 3 closing price of $9.77

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)